SG11201903509QA - Methods and systems for tumor detection - Google Patents

Methods and systems for tumor detection

Info

Publication number
SG11201903509QA
SG11201903509QA SG11201903509QA SG11201903509QA SG11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA SG 11201903509Q A SG11201903509Q A SG 11201903509QA
Authority
SG
Singapore
Prior art keywords
hong kong
international
shatin
subject
cancer
Prior art date
Application number
SG11201903509QA
Other languages
English (en)
Inventor
Eugeni Namsaraev
Yuk-Ming Dennis Lo
Rossa Wai Kwun Chui
Kwan Chee Chan
Peiyong Jiang
Kun Sun
Wai Kei Lam
Original Assignee
Univ Hong Kong Chinese
Grail Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hong Kong Chinese, Grail Inc filed Critical Univ Hong Kong Chinese
Publication of SG11201903509QA publication Critical patent/SG11201903509QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/05—Epstein-Barr virus
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Primary Health Care (AREA)
SG11201903509QA 2016-10-24 2017-10-24 Methods and systems for tumor detection SG11201903509QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662411929P 2016-10-24 2016-10-24
US201762450541P 2017-01-25 2017-01-25
US201762507154P 2017-05-16 2017-05-16
PCT/US2017/058099 WO2018081130A1 (en) 2016-10-24 2017-10-24 Methods and systems for tumor detection

Publications (1)

Publication Number Publication Date
SG11201903509QA true SG11201903509QA (en) 2019-05-30

Family

ID=62025423

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903509QA SG11201903509QA (en) 2016-10-24 2017-10-24 Methods and systems for tumor detection

Country Status (9)

Country Link
US (2) US11459616B2 (zh)
EP (1) EP3535415A4 (zh)
CN (1) CN110100013A (zh)
AU (1) AU2017347790A1 (zh)
CA (1) CA3041647A1 (zh)
MY (1) MY195527A (zh)
SG (1) SG11201903509QA (zh)
TW (2) TWI797095B (zh)
WO (1) WO2018081130A1 (zh)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625288T3 (es) 2011-04-15 2017-07-19 The Johns Hopkins University Sistema de secuenciación segura
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
AU2013338393B2 (en) 2012-10-29 2017-05-11 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
EP2986742A4 (en) * 2014-01-10 2016-12-07 Bio Rad Laboratories Inc INTERCALING DYES FOR DIFFERENTIAL DETECTION
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
EP4198146A3 (en) 2016-03-25 2023-08-23 Karius, Inc. Methods using synthetic nucleic acid spike-ins
AU2017347790A1 (en) 2016-10-24 2019-05-23 Grail, Inc. Methods and systems for tumor detection
MY197535A (en) * 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
US11319602B2 (en) * 2017-02-07 2022-05-03 Tcm Biotech Internationl Corp. Probe combination for detection of cancer
WO2019020057A1 (en) * 2017-07-26 2019-01-31 The Chinese University Of Hong Kong ENHANCING CANCER SCREENING WITH ACELLULAR VIRAL NUCLEIC ACIDS
WO2019067092A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
AU2019261597A1 (en) * 2018-04-24 2020-11-19 Grail, Llc Systems and methods for using pathogen nucleic acid load to determine whether a subject has a cancer condition
CA3107359A1 (en) * 2018-07-23 2020-01-30 The Chinese University Of Hong Kong Cell-free dna damage analysis and its clinical applications
US10721069B2 (en) 2018-08-18 2020-07-21 Eygs Llp Methods and systems for enhancing privacy and efficiency on distributed ledger-based networks
US11168373B2 (en) 2018-09-17 2021-11-09 The University Of North Carolina At Chapel Hill Method for quantifying DNA fragments in a sample by size
JP2022511243A (ja) * 2018-10-08 2022-01-31 フリーノム ホールディングス，インク． 転写因子プロファイリング
EP3864656A1 (en) * 2018-10-12 2021-08-18 Life Technologies Corporation Methods and systems for evaluating microsatellite instability status
EP3884087A4 (en) * 2018-11-21 2022-09-07 Karius Inc. DETECTION AND PREDICTION OF INFECTIOUS DISEASES
CA3123474A1 (en) * 2018-12-19 2020-06-25 The Chinese University Of Hong Kong Cell-free dna end characteristics
EP3696279A1 (en) * 2019-02-13 2020-08-19 Nipd Genetics Public Company Limited Methods for noninvasive prenatal testing of fetal abnormalities
EP3696278A1 (en) * 2019-02-13 2020-08-19 Nipd Genetics Public Company Limited Method of determining the origin of nucleic acids in a mixed sample
CN113710818A (zh) * 2019-04-02 2021-11-26 格里尔公司 病毒相关联的癌症风险分层
US11316691B2 (en) 2019-04-15 2022-04-26 Eygs Llp Methods and systems for enhancing network privacy of multiple party documents on distributed ledger-based networks
US11206138B2 (en) * 2019-05-02 2021-12-21 Ernst & Young U.S. Llp Biosignature-based tokenization of assets in a blockchain
EP3969622A1 (en) * 2019-05-13 2022-03-23 Grail, Inc. Model-based featurization and classification
US11869661B2 (en) 2019-05-22 2024-01-09 Grail, Llc Systems and methods for determining whether a subject has a cancer condition using transfer learning
US20210065842A1 (en) 2019-07-23 2021-03-04 Grail, Inc. Systems and methods for determining tumor fraction
US11232439B2 (en) 2019-08-09 2022-01-25 Eygs Llp Methods and systems for preventing transaction tracing on distributed ledger-based networks
CN115004628A (zh) 2019-11-20 2022-09-02 艾格斯有限责任公司 用于基于可替代和不可替代代币在基于分布式分类账的网络内识别和安全存储分布式分类账中的区分特点的系统、装置和方法
WO2021139716A1 (en) * 2020-01-08 2021-07-15 The Chinese University Of Hong Kong Biterminal dna fragment types in cell-free samples and uses thereof
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
CN115244622A (zh) 2020-02-28 2022-10-25 格瑞尔有限责任公司 使用甲基化测序数据调用变体的系统和方法
WO2021174072A1 (en) 2020-02-28 2021-09-02 Grail, Inc. Identifying methylation patterns that discriminate or indicate a cancer condition
WO2021178613A1 (en) 2020-03-04 2021-09-10 Grail, Inc. Systems and methods for cancer condition determination using autoencoders
CN115552037A (zh) 2020-03-16 2022-12-30 北卡罗来纳大学教堂山分校 用于选择性检测肿瘤源性病毒dna的组合物和方法
US20210302425A1 (en) * 2020-03-26 2021-09-30 Deborah Ann Payne Methods for detecting the presence of bacteria, fungi, parasites, and viruses in a test sample and treating a patient
MX2022012949A (es) 2020-04-15 2023-03-16 Eygs Llp Fichas inteligentes de afirmacion para autentificar y controlar comunicaciones de red utilizando registro distribuido.
US20210398617A1 (en) * 2020-06-19 2021-12-23 Tempus Labs, Inc. Molecular response and progression detection from circulating cell free dna
JP2023530463A (ja) * 2020-06-20 2023-07-18 グレイル エルエルシー ヒトパピローマウイルス関連癌の検出および分類
EP4178448A1 (en) * 2020-07-10 2023-05-17 Progenics Pharmaceuticals, Inc. Methods of making prostate cancer treatment decisions
CN111898694B (zh) * 2020-08-07 2021-09-17 广东电网有限责任公司计量中心 一种基于随机树分类的非入侵式负荷识别方法及装置
WO2022054086A1 (en) * 2020-09-08 2022-03-17 Indx Technology (India) Private Limited A system and a method for identifying genomic abnormalities associated with cancer and implications thereof
CN112149036B (zh) * 2020-09-28 2023-11-10 微梦创科网络科技（中国）有限公司 一种批量非正常互动行为的识别方法及系统
JP2023553113A (ja) * 2020-12-08 2023-12-20 ザ チャイニーズ ユニバーシティ オブ ホンコン 尿及び他のｄｎａの特徴を使用する方法
CN113160889B (zh) * 2021-01-28 2022-07-19 人科(北京)生物技术有限公司 一种基于cfDNA组学特性的癌症无创早筛方法
IL310649A (en) 2021-08-05 2024-04-01 Grail Llc Emergence of a somatic variant together with abnormal methylated segments
CN114023442B (zh) * 2021-11-12 2023-07-14 上海市第一人民医院 基于多组学数据骨肉瘤分子分型的生信分析方法及模型
US11788152B2 (en) * 2022-01-28 2023-10-17 Flagship Pioneering Innovations Vi, Llc Multiple-tiered screening and second analysis
TW202342765A (zh) * 2022-02-07 2023-11-01 香港商創新診斷科技中心 用於量測甲基化及疾病之片段化
AU2023220947A1 (en) * 2022-02-16 2024-01-18 Illumina, Inc. Minimizing fetal fraction bias in maternal polygenic risk score estimation
WO2023170298A1 (en) * 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
DE60207979T2 (de) 2002-03-05 2006-09-28 Epigenomics Ag Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
EP1524321B2 (en) 2003-10-16 2014-07-23 Sequenom, Inc. Non-invasive detection of fetal genetic traits
CA2562310A1 (en) 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
CN1790021A (zh) 2004-12-15 2006-06-21 杨华显 利用循环伊波病毒dna对前癌、原位癌和癌病灶的筛查
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
PT2385143T (pt) 2006-02-02 2016-10-18 Univ Leland Stanford Junior Rastreio genético fetal não-invasivo por análise digital
DK2351858T3 (da) 2006-02-28 2015-04-07 Univ Louisville Res Found Påvisning af føtale kromosomabnormiteter ved anvendelse af tandem-enkeltnukleotid-polymorfismer
US7842482B2 (en) 2007-02-26 2010-11-30 The Chinese University Of Hong Kong Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer
CA2694007C (en) 2007-07-23 2019-02-26 The Chinese University Of Hong Kong Determining a nucleic acid sequence imbalance
US20100112590A1 (en) 2007-07-23 2010-05-06 The Chinese University Of Hong Kong Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
US20120021428A1 (en) 2009-03-31 2012-01-26 Marcus Otte Method for diagnosis of cancer and monitoring of cancer treatments
EP2483426A4 (en) 2009-10-02 2013-04-10 Ct For Addiction And Mental Health METHOD FOR ANALYZING METHYLATION PROFILES OF ACELLULAR CIRCULATING DNA IN BODY FLUIDS
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
HRP20230134T1 (hr) 2009-11-05 2023-03-31 The Chinese University Of Hong Kong Analiza genoma fetusa iz biološkog uzorka majke
MX2012005217A (es) 2009-11-06 2012-07-23 Univ Hong Kong Chinese Analisis genomico a base de tamaño.
CA2796578C (en) 2010-04-16 2021-11-23 Chronix Biomedical Breast cancer associated circulating nucleic acid biomarkers
EP2426217A1 (en) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
AU2011335891B2 (en) 2010-11-30 2015-03-26 The Chinese University Of Hong Kong Detection of genetic or molecular aberrations associated with cancer
US20120190020A1 (en) 2011-01-25 2012-07-26 Aria Diagnostics, Inc. Detection of genetic abnormalities
US20140178348A1 (en) 2011-05-25 2014-06-26 The Regents Of The University Of California Methods using DNA methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
CN113388606A (zh) 2011-09-26 2021-09-14 凯杰有限公司 用于分离细胞外核酸的快速方法
ES2729554T3 (es) 2011-10-21 2019-11-04 Chronix Biomedical Biomarcadores de ácidos nucleicos en circulación asociados al cáncer colorrectal
WO2013060762A1 (en) 2011-10-25 2013-05-02 Roche Diagnostics Gmbh Method for diagnosing a disease based on plasma-dna distribution
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
WO2014004726A1 (en) 2012-06-26 2014-01-03 Caifu Chen Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer
US10988803B2 (en) 2014-12-29 2021-04-27 Life Genetics Lab, Llc Multiplexed assay for quantitating and assessing integrity of cell-free DNA in biological fluids for cancer diagnosis, prognosis and surveillance
SG11201501662TA (en) 2012-09-04 2015-05-28 Guardant Health Inc Systems and methods to detect rare mutations and copy number variation
WO2014043763A1 (en) 2012-09-20 2014-03-27 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
US20150119260A1 (en) 2013-10-18 2015-04-30 National Taiwan University Circulating cancer biomarker and its use
WO2015159292A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
MA39951A (fr) 2014-05-09 2017-03-15 Lifecodexx Ag Détection de l'adn provenant d'un type spécifique de cellule et méthodes associées
US9840742B2 (en) 2014-06-16 2017-12-12 JBS Science Inc. Detection of hepatitis B virus (HBV) DNA and methylated HBV DNA in urine of patients with HBV-associated hepatocellular carcinoma
US20160002717A1 (en) 2014-07-02 2016-01-07 Boreal Genomics, Inc. Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease
TWI813141B (zh) 2014-07-18 2023-08-21 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
JP2017522908A (ja) 2014-07-25 2017-08-17 ユニヴァーシティ オブ ワシントン セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
LT3201361T (lt) 2014-10-01 2020-06-10 Chronix Biomedical Laisvai cirkuliuojančios dnr kiekybinio įvertinimo būdai
EP3227464B1 (en) 2014-12-05 2022-04-20 Foundation Medicine, Inc. Multigene analysis of tumor samples
US11072814B2 (en) * 2014-12-12 2021-07-27 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
US11242559B2 (en) 2015-01-13 2022-02-08 The Chinese University Of Hong Kong Method of nuclear DNA and mitochondrial DNA analysis
US10364467B2 (en) * 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US10319463B2 (en) 2015-01-23 2019-06-11 The Chinese University Of Hong Kong Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations
DK3256605T3 (da) 2015-02-10 2022-03-14 Univ Hong Kong Chinese Påvisning af mutationer til cancerscreening og føtal analyse
CA2980078C (en) 2015-03-16 2024-03-12 Personal Genome Diagnostics Inc. Systems and methods for analyzing nucleic acid
KR20180031742A (ko) 2015-07-23 2018-03-28 더 차이니즈 유니버시티 오브 홍콩 무세포 dna의 단편화 패턴 분석
US10428391B2 (en) 2015-07-27 2019-10-01 The Johns Hopkins University Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: PCR and sequencing based process methods
CN108603236A (zh) 2015-12-18 2018-09-28 路胜基因（新加坡）私人有限公司 检测和定量微生物的靶核酸序列
AU2017347790A1 (en) 2016-10-24 2019-05-23 Grail, Inc. Methods and systems for tumor detection
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
WO2019020057A1 (en) 2017-07-26 2019-01-31 The Chinese University Of Hong Kong ENHANCING CANCER SCREENING WITH ACELLULAR VIRAL NUCLEIC ACIDS

Also Published As

Publication number Publication date
US20180237863A1 (en) 2018-08-23
EP3535415A4 (en) 2020-07-01
TW201833329A (zh) 2018-09-16
CA3041647A1 (en) 2018-05-03
AU2017347790A1 (en) 2019-05-23
US11459616B2 (en) 2022-10-04
EP3535415A1 (en) 2019-09-11
TWI797095B (zh) 2023-04-01
WO2018081130A1 (en) 2018-05-03
US20230132951A1 (en) 2023-05-04
CN110100013A (zh) 2019-08-06
TW202340477A (zh) 2023-10-16
MY195527A (en) 2023-01-30

Similar Documents

Publication Publication Date Title
SG11201903509QA (en) Methods and systems for tumor detection
SG11201906397UA (en) Diagnostic applications using nucleic acid fragments
Harrell et al. Statistical comparison of Afirma GSC and Afirma GEC outcomes in a community endocrine surgical practice: early findings
SG11201908396PA (en) Methods of treating tumor
SG11201903158RA (en) Methods for cell label classification
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
CN103993069B (zh) 病毒整合位点捕获测序分析方法
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201906938WA (en) Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201903519UA (en) Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
SG11201908509TA (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
SG11201803666WA (en) Single image detection
SG11201805119QA (en) Methods to determine tumor gene copy number by analysis of cell-free dna
SG11201810924WA (en) System and method for secondary analysis of nucleotide sequencing data
SG11201907663XA (en) Method and device for constructing scoring model and evaluating user credit
SG11201901783UA (en) A device to manipulate ions of same or different polarities
SG11201806100PA (en) Apparatus of plural charged-particle beams
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201900509YA (en) Simultaneous capturing of overlay signals from multiple targets
SG11201811408PA (en) Adoptive cell transfer and oncolytic virus combination therapy
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer